Oral Microencapsulated Live Saccharomyces cerevisiae Cells for Use in Renal Failure Uremia: Preparation and In Vivo Analysis by Coussa, Razek et al.
Hindawi Publishing Corporation
Journal of Biomedicine and Biotechnology
Volume 2010, Article ID 620827, 7 pages
doi:10.1155/2010/620827
Research Article
OralMicroencapsulatedLiveSaccharomycescerevisiae Cells for
Use in Renal Failure Uremia: Preparation and In Vivo Analysis
Razek Coussa, Christopher Martoni, Jasmine Bhathena, Aleksandra Malgorzata Urbanska,
andSatyaPrakash
Biomedical Technology and Cell Therapy Research Laboratory, Department of Biomedical Engineering, Faculty of Medicine,
McGill University, Duﬀ Medical Building, 3775 University Street, Montr´ eal, QC, Canada H3A 2B4
Correspondence should be addressed to Satya Prakash, satya.prakash@mcgill.ca
Received 9 February 2010; Accepted 21 April 2010
Academic Editor: Ali Khraibi
Copyright © 2010 Razek Coussa et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Orally administrable alginate-poly-L-lysine-alginate (APA) microcapsules containing live yeast cells was investigated for use
in renal failure. At all times, yeast cells remain inside the microcapsules, which are then excreted in the stool. During their
gastrointestinal passage, small molecules, like urea, diﬀuse into the yeast microcapsules where they are hydrolyzed. Orally
administrating these microcapsules to uremic rats was found to decrease urea concentrations from 7.29 ± 0.89mmol/L to
6.12 ± 0.90mmol/L over a treatment period of eight weeks. After stopping the treatment, the urea concentrations increased
back to uremic levels of 7.64 ± 0.77mmol/L. The analysis of creatinine concentrations averaged 39.19 ± 4.33μmol/L, 50.83 ±
5.55μmol/L, and 50.28 ± 7.10μmol/L for the normal-control, uremic-control and uremic-treatment groups, respectively. While
creatinine concentrations for both uremic-control and uremic-treatment groups did not diﬀer among each other (P>. 05),
they were, however, signiﬁcantly higher than those of the normal control group (P<. 0 5 ) .U r i ca c i dc o n c e n t r a t i o n sa v e r a g e d
80.08±26.49μmol/L,99.92±26.55μmol/L,and86.49±28.42μmol/Lforthenormal-control,uremic-controlanduremic-treatment
groups, respectively. There were no signiﬁcant diﬀerences in both calcium and phosphate concentrations among all three groups
(P>. 05). The microbial populations of ﬁve tested types of bacteria were not substantially altered by the presence of the yeast APA
encapsulated yeast (P>. 05).
1.Introduction
In North America, renal failure is quite common, aﬀecting
approximately 5% of hospitalized patients and up to 30%
of patients in intensive care units (ICUs) [1]. In 2003, 8.3
million Americans were reported to have mature chronic
kidney disease with a signiﬁcant number developing end
stage renal disease (ESRD) [2]. Acute renal failure, or ARF,
aﬀects up to 200,000 people in the United States annually,
or approximately 5% of all long-term hospitalized patients
[3–5]. ARF and ESRD have high mortality characterized
by an overall survival rate of approximately 50% or lower
depending on the severity of the renal malfunction [6].
Inmostcasesofrenalfailure,thereisusuallyanincreased
retention of waste metabolites (mainly urea and creatinine)
in the blood and body tissues due to a substantial decrease
in urinary excretion [7–10]. As a result, blood urea nitrogen
(BUN) and creatinine may increase from 18mg/dL to 100–
300mg/dL and from 1mg/dL to 10–25mg/dL, respectively
[11, 12]. Treating renal failure has been a persistent chal-
lenge for almost two decades. Dialysis is generally used
to correct for these excess metabolites [10, 13]. However,
all current renal replacement therapies (RRTs), including
kidney transplantation, dialysis, and hemoﬁltration, display
inherent disadvantages. They are characterized by serious
long term complications that undermine the eﬃcacy of these
renal failure treatment modalities. Hence, new therapeutic
methodologies have been investigated and developed in
order to bridge the gap between eﬃcacy and feasibility.
Among such novel potential treatments is the microen-
capsulation of live microorganisms capable of depleting
toxic wastes and other unwanted metabolites. Previous
research has demonstrated the feasibility and the potential
of administrating microencapsulated micro-organisms as2 Journal of Biomedicine and Biotechnology
an alternative oral therapy. Examples include microencap-
sulating genetically engineered Escherichia coli DH5 cells
over-expressing the Klebsiella aerogenes urease gene for urea
removal in renal failure [14], Oxalobacter formigenes produc-
ing oxalate-degrading enzymes for removal of accumulated
oxalate in urolithiasis [15, 16].
There have been three major attempts to design novel
potential alternative approaches to remove nitrogenous
wastesassociatedwithrenalfailure.Theﬁrstusesadsorbents,
such as oxystarch, to directly bind urea [10–13, 17–20].
The second method consists of hydrolyzing urea via co-
immobilized enzyme urease and removing it via adsorbents
[10, 12, 13, 18–20]. However, using such adsorbents requires
very large doses, which is medically not advisable [11, 17,
18, 21, 22]. The third method consists of microencapsulating
multienzyme systems to convert urea and ammonia into
essential amino acids [13, 18, 22–24]. The problem with the
last method is its poor conversion rate [23, 24].
This article investigates the potential of orally adminis-
trating APA microcapsules containing live yeast cells in renal
failure uremic rates model and its feasibility to reduce the
nitrogenouswasteconcentrationlevels.Towardsthisgoal,we
have recently optimized the encapsulation procedure and its
respective parameters to accommodate yeast cells.
2.MaterialsandMethods
2.1. Chemicals. Sodium alginate (low viscosity) and poly-
L-lysine hydrobromide (PLL) (MW 27,400) were both
purchased from Sigma-Aldrich.
2.2. Microorganism and Culture Conditions. Saccharomyces
cerevisiae,strainreferencenumber9896,waspurchasedfrom
ATCC [24]. This organism is capable of producing urease
urea amidolyase, which in turn metabolizes urea [25]. Yeast
mold broth (YMB) growth medium was used for primary
cell cultivation. YMB is composed of 10g/L of glucose, 3g/L
of malt extract, 5g/L of peptone and 3g/L yeast extract. The
inoculated medium was incubated aerobically at 37
◦Cf o r4 8
hours.
2.3. Preparation of APA Microcapsules Containing Live Yeast
Cells. Log phase cultures of Saccharomyces cerevisiae were
harvested by centrifugation at 3500rpm for 15 minutes at
4◦C. Pellets were then mixed with 2% alginate solution
in order to form a ﬁnal mixture consisting of 8% (v/w)
pellets and 1.75% alginate. Alginate microcapsules were
prepared by generating droplets of sodium alginate solution
(15mg/mL) using an IER-20 encapsulator machine man-
ufactured by Inotech. Corp. Extruded through a 300μm
nozzle by a syringe driven pump, these droplets were gelled
for 30 minutes in a well-stirred calcium chloride solution
(11mg/mL).Thesamedropletswerethencoatedwitha0.1%
(w/v) solution of PLL for 10 minutes to form AP beads and
washed again with physiological saline (PS) for 5 minutes.
The ﬁnal alginate coating was then applied by immersing
the beads in a 0.1% (w/v) sodium alginate solution for 10
minutes followed by a ﬁnal 5-minute PS wash. The resulting
microcapsules, having an average diameter of 638 ± 17μm,
were then collected and stored in a 10/90 YMB/PS solution
at 4◦C. All solutions used in the preparation of these APA
microcapsules were either ﬁltered using 0.22μmﬁ l t e ro r
autoclaved to ensure sterility. Moreover, the entire procedure
was carried out in a biological hood.
2.4. Treatment Phases and Animal Monitoring. In this study,
36 (12 control normal and 24 uremic rats) male Wistar
rats were purchased from Sprague Dawley Laboratory. All
rats’ aged between 60 and 80 days and weighted between
300 and 340g. Both normal and uremic rats were tested
upon arrival for determination of baseline urea levels (18–
30mg/dLor3–5mmol/Lappr o ximatelyfornormalrats).On
arrival, two rats were placed two per cage and fed rodent
chow for 1 week in order to acclimatize them to the facility
(sterile room with controlled temperature (22–24
◦C) and
alternating light and dark cycles). Food and water were
p r o v i d e da dl i b i t u m .T h ea n i m a l sw e r et h e nb er a n d o m i z e d
in 3 groups: (1) normal control-treatment period (TP)
consisting of 12 normal rats fed with alginate-ploy-L-lysine-
alginate (APA) microcapsules containing live yeast cells, (2)
uremic control-no-TP consisting of 12 uremic rats fed with
empty APA microcapsules, and (3) uremic-TP consisting of
12 uremic rats fed with APA microcapsules containing live
yeast cells.
During the experiment, the 3 groups of animals were
monitored over time to evaluate changes in their urea,
creatinine, phosphate, calcium, and uric acid levels. As
mentioned before there was a 1 week pre-TP period to
acclimatize the animals. The treatment period lasted for 8
weeks during which the rats were gavaged daily early in the
afternoon and bled twice a week. The syringes were weighted
in order to verify that the same amount of capsules were
administered to each rat. There was a post-TP period of 2
weeks during which the animals were only bled respecting
the same frequency. Animals were bled approximately 30–45
minutes post gavage.
2.5. Gavaging. 3mL syringes (purchased from Fisher Scien-
tiﬁc)wereusedtogavagetheanimals.Eachsyringecontained
2.5mL of APA microcapsules mixed with 0.5mL of PS. The
loading was conducted in a sterile biological hood using a
beaker ﬁlled with the desired preparation. Before gavaging
the animals, syringes were incubated for 2 hours at 37
◦Ci n
order to activated the microorganisms. The microcapsules
were then orally forced-fed to the experimental rats using
curved 16G stainless steel gavage needle. For this, the animal
was hand-restrained and no anesthesia was used.
2.6. Blood Collection. 200μL of saphenous blood was col-
lected in SST microtainers (purchased from BD Biosciences)
without sedating the animals. The samples were centrifuged
and analyzed using a Hitachi 911 Clinical Chemistry
Analyzer (Roche Diagnostics), which was loaded with the
appropriate kits. Animal health indicators veriﬁcation of
clinical features (body weight, animal’s integument, erythe-
matic, hair coat condition, status of hydration and prorates,Journal of Biomedicine and Biotechnology 3
animal’s equilibrium: unsteadiness on legs, coordination
of legs and/or abnormal reﬂexes, muscular disturbances,
cardiovascular problems, levels of energy and motion rate,
animal’s respiratory system) were monitored and assessed
twice a week for all the entire trial period (11 weeks).
2.7. Eﬀect of Oral Administration of Yeast APA Microcapsules
on the Gut Microbial Flora. To investigate the eﬀect of
oral administration of APA encapsulated yeast on the gut
microﬂora, parts of rats’ large intestine were obtained after
sacriﬁce. From each group, 5 rats were chosen randomly for
this purpose. The organs were homogenized mechanically
until a ﬂuid phase was obtained. Following that, 1mL of this
slurry was collected in a 1.5mL graduated Eppendorf tube.
Six 10-fold serial dilutions were performed using autoclaved
PS and 0.1mL aliquots of ﬁnal dilution were plated on 5
diﬀerent agar plates. The plates were then incubated aerobi-
cally according to their corresponding conditions. Bacterial
enumeration for speciﬁc fecal marker microorganisms, total
aerobes, total anaerobes, Escherichia coli, Staphylococcus sp.
and Lactobacillus sp. was performed in triplicate using an
agar-plate-count assay. The platting media and incubation
conditions used are all listed in Table 1.
2.8. Statistical Analysis. The statistical Analysis System (SAS
Enterprise Guide 4.1 (4.1.0.471) by SAS Institute Inc., Cary,
NC, USA) was used to analyze the data. Data was expressed
as means ± SEM. Group and time eﬀects were statistically
investigated by ANOVA mixed models. Data were considered
signiﬁcant at P<. 05.
3. Results
One of the important parameters indicating the eﬃciency
of the treatment is the body weight, which was measured
twice a week along the trial period. Figure 1 shows the
average body weights of each studied group. The average
body weight of the normal control group increased from
347.83 ± 11.86g at t = 1 week to 464.03 ± 11.86g at
t = 11 weeks, respectively. Similarly, body weights for the
uremic control and uremic treatment groups increased from
341.64±11.86g to 461.73±29.01g, and from 345.50±9.28g
to 465.00 ± 34.56g, respectively, between week 1 and 11 of
the trial. There were signiﬁcant time and group eﬀects in
rats’body weight(P<. 05). The urea concentration, which is
one of the essential indicators of the success of the proposed
treatment, followed a diﬀerent trend (Figure 2). Speciﬁcally,
urea levels in the uremic treatment group during the pre-
TP and post-TP phases were not statistically diﬀerent from
those for the uremic control group (P>. 0 5 ) .H o w e v e r ,u r e a
concentrations for the uremic treatment group in between
weeks 2 and 9 were signiﬁcantly diﬀerent from those for
the other two controls (P<. 05). All along the 11 weeks of
the trial, urea concentrations averaged 5.37 ± 0.67mmol/L
and 7.39 ± 0.99mmol/L for the normal and uremic control
groups, respectively. The average urea concentration for the
uremic treatment group decreased from 7.29 ± 0.89mmol/L
to 6.97 ± 0.48mmol/L after 1 week of treatment. During
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Figure 1: Rats’ body weight before, during and after oral adminis-
tration of APA microencapsulated yeast cells.
0
1
2
3
4
5
6
7
8
9
U
r
e
a
c
o
n
c
e
n
t
r
a
t
i
o
n
(
m
m
o
l
/
L
)
123456789 1 0 1 1
Time (weeks)
Group 1: normal/Tx
Group 2: uremic/control
Group 3: uremic/Tx
Pre-TP
(no gavaging) TP
Post-TP
(no gavaging)
Figure 2: Plasma urea concentration before, during and after oral
administration of APA microencapsulated yeast cells.
the treatment, the urea concentration for this same group
averaged6.01±0.47mmol/Lbeforeincreasingagainto7.64±
0.77mmol/L once the gavage had stopped.
The analysis of creatinine concentrations averaged
39.19 ± 4.33μmol/L, 50.83 ± 5.55μmol/L, and 50.28 ±
7.10μmol/L for the normal and uremic control as well as
the uremic treatment group, respectively (Figure 3). While
values for both uremic groups did not diﬀer among each
other (P>. 05), they were, however, signiﬁcantly higher than
those of the normal control group (P<. 05).
Uric acid concentrations averaged 80.08 ± 26.49μmol/L,
99.92 ± 26.55μmol/L, and 86.49 ± 28.42μmol/L for the
normal and uremic control as well as the uremic treat-
ment group, respectively (Figure 4). Calcium concentrations
averaged 2.65 ± 0.25mmol/L, 2.66 ± 0.15mmol/L, and4 Journal of Biomedicine and Biotechnology
Table 1: Media and incubation conditions used for enumeration of representative microbes in the human large intestine.
Microbial group Medium Incubation conditions and time Colonies formed
Total aerobes Brain heart infusion agar Aerobic, 37C, 24h White
Total anaerobes Brain heart infusion agar Anaerobic, 37C, 72h White
Escherichia coli Mc Conkey agar Aerobic, 43C, 24h Red-purple
Staphylococcus sp. Mannitol Salt agar Aerobic, 37C, 48h White with yellow/purple zone
Lactobacillus sp. Rogosa agar Anaerobic, 37C, 72h White
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Figure 3: Plasma creatinine concentration before, during and after
oral administration of APA microencapsulated yeast cells.
2.63 ± 0.22mmol/L for the normal, uremic-control and
uremic treatment groups, respectively (Figure 5). There were
neither time nor group eﬀects in the data for calcium
concentrations (P>. 05). Finally, phosphate concentrations,
whichaveraged2.84±0.31mmol/L, 2.78±0.28mmol/L, and
2.75±0.33mmol/L(Figure6)forthenormal,uremic-control
and uremic treatment groups, respectively, did not display
any time or group eﬀects (P>. 05).
An important prerequisite when orally administrating
APA microcapsules containing live yeast cells is that these
entities should not disturb the natural colonic gut ﬂora. This
importanceisaccentuatedwhenprolongedandrepeatedoral
intakeoflargequantitiesofmicrocapsulesisrequired.Table2
shows no marked diﬀerences in the population of the tested
microbes for the uremic treatment group and those for both
the normal and uremic control groups (P >. 05).
4. Discussion
The rationale behind using an experimental uremic rat
animal model stems from the striking similarities in the GI
tract of rats and humans. In particular, this experimental
uremic rat model has shown earlier high levels of plasma
urea and other unwanted metabolites compared to normal
rats, with a similar experimental endpoint. With 12 animals
in each group, diﬀerences in mean uremic metabolites could
be determined with a power larger than 80% and an alpha
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Figure 4: Plasma uric acid concentration before, during and after
oral administration of APA microencapsulated yeast cells.
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Figure 5: Plasma calcium concentration before, during and after
oral administration of APA microencapsulated yeast cells.
error of 5%. In other words, using 36 animals allows us to
detect small diﬀerences, if any exist, and, thus, infer properly
about the feasibility of the treatment.
The major objective of this animal study was to deter-
mine the eﬃcacy of microencapsulated live saccharomyces
cerevisiae cells as a treatment option for lowering toxic
metabolites associated with renal failure. For the ﬁrst time,Journal of Biomedicine and Biotechnology 5
Table 2: Eﬀect of APA microcapsules on selected microbes in the human large intestine.
Microbes Incubation time [hr] Log CFU/ml medium
Normal-TP Uremic-empty APA microcapsules Uremic-TP
Total aerobes
08 .22 ±0.12 8.22 ±0.11 8.22 ±0.09
68 .27 ±0.01 8.17 ±0.16 8.26 ±0.08
12 8.24 ±0.14 8.34 ±0.04 8.31 ±0.07
24 8.29 ±0.18 .32 ±0.02 8.28 ±0.03
Total anaerobes
08 .37 ±0.03 8.37 ±0.01 8.37 ±0.01
68 .35 ±0.09 8.39 ±0.02 8.31 ±0.1
12 8.38 ±0.11 8.41 ±0.07 8.38 ±0.12
24 8.37 ±0.14 8.4 ±0.11 8.36 ±0.16
Escherichia coli
08 .29 ±0.13 8.29 ±0.08 8.29 ±0.11
68 .24 ±0.16 8.33 ±0.05 8.29 ±0.12
12 8.27 ±0.11 8.24 ±0.17 8.32 ±0.1
24 8.31 ±0.07 8.28 ±0.12 8.27 ±0.11
Staphylococcus sp.
06 .65 ±0.14 6.65 ±0.12 6.65 ±0.1
66 .74 ±0.07 6.57 ±0.16 6.72 ±0.03
12 6.59 ±0.15 6.61 ±0.06 6.69 ±0.01
24 6.64 ±0.13 6.62 ±0.12 6.58 ±0.08
48 6.71 ±0.07 6.74 ±0.12 6.6 ±0.17
Lactobacillus sp.
05 .32 ±0.01 5.32 ±0.06 5.32 ±0.03
65 .4 ±0.05 5.41 ±0.01 5.36 ±0.08
12 5.45 ±0.03 5.39 ±0.05 5.33 ±0.11
24 5.39 ±0.09 5.37 ±0.12 5.37 ±0.11
48 5.36 ±0.15 .35 ±0.08 5.41 ±0.01
72 5.38 ±0.17 5.42 ±0.12 5.45 ±0.15
0
1
2
3
4
5
P
h
o
s
p
h
a
t
e
c
o
n
c
e
n
t
r
a
t
i
o
n
(
m
m
o
l
/
L
)
1234567891 0 1 1
Time (weeks)
Group 1: normal/Tx
Group 2: uremic/control
Group 3: uremic/Tx
Pre-TP
(no gavaging) TP
Post-TP
(no gavaging)
Figure 6: Plasma phosphate concentration before, during and after
oral administration of APA microencapsulated yeast cells.
we report the use of polymeric membrane artiﬁcial cells [26–
29] containing live yeast cells in renal failure. Our studies
show that live yeast cells can be microencapsulated and
retained inside the artiﬁcial cells during passage down the GI
tract. During passage through the intestine, urea molecules
diﬀuse throughout the permeable membrane of the artiﬁcial
cells. This is rendered possible due to the molecular-weight-
cut-oﬀ (MWCO) of these artiﬁcial cells. In particular, the
MWCO of the alginic membrane is estimated to be between
60–70kDa [30], while the approximate molecular weight
of urea and urease are 60kDa and 483kDa, respectively.
Theoretically speaking, urease should always stay entrapped
inside the cell. Once inside the cell, urea molecules get
hydrolyzed due to yeast cells, which use urea as their carbon
source.Thesamereasoningappliesfortheothermetabolites.
In humans, normal urea concentration ranges approx-
imately between 3–5 ± 0.5mmol/L (or 18–30mg/dL) in
plasma. Anything above this range is considered uremic. The
ureaconcentrationsofthenormalanduremiccontrolgroups
are expected to be within and higher than the normal urea
range of 3–5 ± 0.5 mmol/L (Figure 2). Noting that the urea
concentrations of the uremic treatment group decreased at
thestartofthetreatmentandincreasedtouremicvaluesafter
stopping the treatment suggests that the APA encapsulated
yeast show eﬃcacy and work as hypothesized. By analyzing
the data, one can notice that urea in uremic treated rats
decreased by approximately 18% from the pre-TP phase
level. During the treatment 8-week treatment period, the
urea concentrations for the uremic-TP group stagnated
around6.01±0.47mmol/L,whichisaround1.1timesgreater
than the average urea concentration of the normal control
group. Upon terminating the oral administration of the APA
encapsulated yeast, the plasma urea level returned rapidly to
the uremic values (Figure 2). This means that the artiﬁcial6 Journal of Biomedicine and Biotechnology
cells were all excreted in the stool and were not retained in
the intestinal tract.
The concentrations of creatinine and uric acid (Figures
3 and 4) did not vary signiﬁcantly within and among each
uremic group but were signiﬁcantly diﬀerent from those of
the control group. Speciﬁcally, the creatinine concentrations
of uremic treated and not treated groups were 1.29 and 1.28
times greater than those of the normal group, respectively.
Similarly, those of uric acid for the same uremic groups
were 1.23 and 1.07 times greater than those of the normal
group, respectively. These trends suggests that the orally
administered APA encapsulated yeast did not have any eﬀect
on lowering neither creatinine nor uric acid, which are both
correlated with decreased renal function [31, 32]. Similarly,
the artiﬁcial cells did not inﬂuence calcium (P>. 05) and
phosphate (P>. 05) plasma electrolytes because there was
no variation in their concentrations neither with respect to
time nor among groups (Figures 5 and 6).
Body weight, which is an indication of the overall health
condition, increased throughout the trial period (Figure 1).
This suggeststhat the animals maintained a constant growth.
Furthermore, each rats’ group displayed body weight values
that are statistically diﬀerent from the other two groups
with respect to time. However, renal failure individuals have
usually their body weight decreasing with time. If the TP is
proven successful, we would have expected the body weight
of the uremic control rats to decrease and that of the normal
and uremic-TP groups to increase. Speciﬁcally, the body
weight of the normal and uremic controls increased by
33.41±2.1% and 35.15±1.9%, respectively, at the end of the
11th week. Similarly, the uremic-TP had their body weight
increasedby34.59±0.9%.DuringtheTPperiod,theincrease
in the body weight of the uremic-TP group is signiﬁcantly
larger than that of the uremic control group. This fact is
not surprising and suggests that the treatment is somehow
eﬀective in alleviating some of the uremia eﬀects. However,
theonlypossibleexplanationtotheriseinthebodyweightof
the uremic control rats is that the decrease in this parameter
due to uremia is outweighed by its increase due to growth.
It is known that a well-balanced gut microbiota plays
a crucial role on the ensemble of the human health [33];
upsetting the intestinal ﬂora may lead to complications and
colonizations/infections [34]. The results from the in vivo
viability study (Table 2) could suggest that the materials
used to produce the microcapsules combined with the yeast
itself did not evoke any appreciable adverse eﬀects on the
simulated human intestinal ﬂora.
5. Conclusion
Normally, the kidneys are responsible for removing
metabolic waste metabolites and maintaining water and
electrolyte balance. In the case of renal failure, these tasks
cannot be fulﬁlled by the damaged kidneys and patients
need alternative treatment to survive. Dialysis and kidney
transplantation are considered eﬀective but expensive. Other
alternatives such as the use of absorbents are challenged
with the need of large doses of absorbents [10–13, 17–
20]. This work presents a novel yeast-based approach to
treat renal failure uremia. Oral administration of these
microcapsules to uremic rats was found to decrease urea
levels by 18 ± 0.31% over a period of eight weeks. After
stopping the treatment, the urea concentration increased
back to the uremic values. However, this formulation had no
perceivable eﬀects on the concentrations of creatinine, uric
acid, phosphate, and calcium. The microbial populations
of the ﬁve tested types of bacteria were not substantially
altered by the presence of the APA encapsulated yeast. This
suggets, in consequence, that there were no perceivable
adverse eﬀects of oral administration of these capsules on
the microbial ﬂora of the human GI tract.
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